In a data set related to nonalcoholic fatty liver disease (GSE135251) (Govaere et al. 2020), Anxa6 mRNA levels were significantly elevated in both nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) liver of patients across different disease stages (Figure S1A). Here, ANXA6 is linked to metabolic dysfunction-associated steatohepatitis.